Scotiabank lowered the firm’s price target on Biomea Fusion (BMEA) to $10 from $30 and keeps an Outperform rating on the shares. The firm cut its price target on the stock due to the extended icovamenib type-2 diabetes timelines, reflecting the need for an additional Phase 2b study prior to any Phase 3 study, as well as increased equity dilution, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMEA: